Alphatec Holdings Inc (ATEC) stock hit a 52-week low of $6.80, down 65.55% from its 52-week high of $23.29. The company maintains a market capitalization of $1.06 billion.
The decline follows third-quarter 2026 earnings that missed expectations. ATEC reported adjusted earnings of $0.09 per share versus a forecast of $0.10, and revenue of $221.17 million below the expected $225.44 million. The company posted 13% year-over-year revenue growth but faced softer biologics sales and reduced its full-year outlook.
InvestingPro data indicates the stock is undervalued relative to its Fair Value estimate. Analysts predict the company will be profitable this year. ATEC posted 15% revenue growth with a 71% gross profit margin in the last twelve months.
TD Cowen lowered its price target to $10 from $13, maintaining a Buy rating and citing intensified biologics headwinds and market slowdown. Needham adjusted its price target to $12 from $14, also maintaining a Buy rating due to the revenue miss and reduced guidance.